Background
The thinking about how to best treat Alzheimer’s disease has advanced over the past few years to treating with two drugs, one that removes amyloid plaque from the brain (which removes the cause of the disease) and one that removes the protein tau (which removes the cause of brain cell death). The more brain cells that are lost, the more memory loss is experienced by the individual.
The combination drug study that we are currently conducting provides a standard-of-care amyloid-removing medication and a tau-protein removing medication that seeks to reduce or stop brain cell death and memory loss
Criteria to participate
Some of the criteria patients must satisfy to participate are:
- Male or female between 50 and 80 years old
- Have a study partner (i.e. someone who is with you for 8 hours or more each week and would be willing to come to the study center about twice a year with you)
- Demonstrates mild memory loss with testing
- Found to have amyloid brain plaque and toxic tau particles in the circulation
- Is able to have an MRI scan (e.g. no metal in your head or upper torso)
- Has no medical conditions which may also cause memory loss (e.g. Parkinson’s, uncontrolled sleep apnea, and history or stroke)
About the Study
Once the study criteria are met, the patient will receive lecanemab (Leqembi) once weekly (administered at home) for 79 weeks. In addition, the patient will receive either the anti-tau study medication (78% chance) or a placebo (22% chance) for 79 weeks (administered once monthly in the research center). Patients will receive MRI and PET scans of the brain, blood tests, and periodic memory testing during the study. The study will last about 2 years. There is no cost to the patient for medical care provided in the study nor for any of the scans, memory testing, or medication and may receive compensation for time and travel expenses.
Current Studies
We are currently conducting the following studies with medications which seek to stabilize tau protein
Study |
Sponsor |
Study medication |
NCT number |
Study Status |
E2814-G000-202 | Eisai | E2814 | NCT06602258 | Enrolling |
You may use the NCT number to learn more about the study we are conducting by going to clinicaltrials.gov and entering the number in the search bar.